Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C22H29NO5.C4H4O4 |
| Molecular Weight | 503.5415 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C2=CC=CC=C2
InChI
InChIKey=FSRLGULMGJGKGI-BTJKTKAUSA-N
InChI=1S/C22H29NO5.C4H4O4/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5;5-3(6)1-2-4(7)8/h8-14H,7,15H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] is a noncompetitive spasmolytic agent. The actions of trimebutine on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral mu, kappa and delta opiate receptors and (ii) release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon. Trimebutine attenuated colonic motility mainly through the inhibition of L-type Ca(2+) channels at higher concentrations, whereas, at lower concentrations, it depolarized membrane potentials by reducing BK(ca) currents, resulting in the enhancement of the muscle contractions.Trimebutine accelerates gastric emptying, induces premature phase III of the migrating motor complex in the intestine and modulates the contractile activity of the colon. It is indicated for the treatment and relief of symptoms associated with the irritable bowel syndrome (spastic colon); and in postoperative paralytic ileus in order to accelerate the resumption of the intestinal transit following abdominal surgery.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TRIMEBUTINE Approved UseTRIMEBUTINE (trimebutine maleate) is indicated:
– for the treatment and relief of symptoms associated with the irritable bowel syndrome (spastic colon); and
– in postoperative paralytic ileus in order to accelerate the resumption of the intestinal transit following abdominal surgery. |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride. | 1991 Jun |
|
| Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation. | 1993 Dec 7 |
|
| Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function. | 2001 Aug |
|
| Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. | 2001 Aug |
|
| [HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. | 2001 Feb |
|
| Determination of trimebutine maleate in rat plasma and tissues by using capillary zone electrophoresis. | 2001 Jun |
|
| Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. | 2001 Mar |
|
| Allergic contact dermatitis due to trimebutine. | 2001 Sep |
|
| The role of remote gut inflammation in duodenojejunal dysmotility. | 2002 Apr |
|
| [Prokinetics of gastrointestinal system; its newer aspects with regard to motillity stimulants]. | 2002 Feb |
|
| Oesophageal motility disorders. | 2002 Jan 12 |
|
| Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. | 2002 Mar |
|
| Quantitative determination of trimebutine maleate and its three metabolites in human plasma by liquid chromatography-tandem mass spectrometry. | 2002 Nov 5 |
|
| Factors affecting gallbladder motility: drugs. | 2003 Jul |
|
| Spectrophotometric and liquid chromatographic determination of trimebutine maleate in the presence of its degradation products. | 2003 Sep 19 |
|
| Acute treatment of migraine. Breaking the paradigm of monotherapy. | 2004 Jan 28 |
|
| [Abdominal migraine as a cause of chronic recurrent abdominal pain in a 9-years-old girl--case report]. | 2005 Aug |
|
| Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. | 2005 Jun |
|
| Effect of nor-trimebutine on neuronal activation induced by a noxious stimulus or an acute colonic inflammation in the rat. | 2005 Oct 21 |
|
| Prokinetic agents in childen with poor appetite. | 2005 Oct-Dec |
|
| Pharmacokinetic study of trimebutine maleate in rabbit blood using in vivo microdialysis coupled to capillary electrophoresis. | 2005 Sep 15 |
|
| The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. | 2006 |
|
| Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. | 2006 Jul |
|
| Spectrophotometric determination of some anti-tussive and anti-spasmodic drugs through ion-pair complex formation with thiocyanate and cobalt(II) or molybdenum(V). | 2007 Apr |
|
| Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method. | 2007 Jan |
|
| Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. | 2007 Mar |
|
| Activation of peripheral opioid receptors has no effect on heart rate variability. | 2008 Jun |
|
| Effect of four medications associated with gastrointestinal motility on Oddi sphincter in the rabbit. | 2009 |
|
| Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. | 2009 Apr |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. | 2010 Mar |
Patents
Sample Use Guides
The adult recommended dose is up to 600 mg daily in divided doses. It may be administered as two 100 mg tablets three times daily before meals or one 200 mg tablet three times daily before meals.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
58997-92-5
Created by
admin on Sat Dec 16 11:50:24 GMT 2023 , Edited by admin on Sat Dec 16 11:50:24 GMT 2023
|
PRIMARY | |||
|
H4XZJ9GX7T
Created by
admin on Sat Dec 16 11:50:24 GMT 2023 , Edited by admin on Sat Dec 16 11:50:24 GMT 2023
|
PRIMARY | |||
|
261-550-7
Created by
admin on Sat Dec 16 11:50:24 GMT 2023 , Edited by admin on Sat Dec 16 11:50:24 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
